Cooper Companies (NASDAQ:COO) Lowered to “Hold” Rating by Robert W. Baird

Robert W. Baird downgraded shares of Cooper Companies (NASDAQ:COO) from a strong-buy rating to a hold rating in a research note published on Thursday morning,Zacks reports.

COO has been the topic of several other reports. Bank of America reaffirmed a “neutral” rating and issued a $65.00 target price (down from $80.00) on shares of Cooper Companies in a research report on Thursday. Piper Sandler lowered Cooper Companies from an “overweight” rating to a “neutral” rating and dropped their price target for the stock from $86.00 to $59.00 in a research note on Thursday. KeyCorp restated a “sector weight” rating on shares of Cooper Companies in a report on Friday, June 5th. Stifel Nicolaus set a $70.00 price objective on Cooper Companies and gave the company a “buy” rating in a research note on Thursday. Finally, Mizuho set a $75.00 target price on Cooper Companies in a report on Thursday. Five analysts have rated the stock with a Buy rating, eleven have assigned a Hold rating and two have assigned a Sell rating to the stock. Based on data from MarketBeat, Cooper Companies presently has a consensus rating of “Hold” and an average target price of $71.47.

Cooper Companies Trading Down 14.7%

Shares of COO stock opened at $54.17 on Thursday. Cooper Companies has a 1-year low of $51.01 and a 1-year high of $89.83. The firm’s 50-day simple moving average is $72.02 and its 200-day simple moving average is $69.81. The firm has a market cap of $10.56 billion, a P/E ratio of 18.49, a PEG ratio of 1.66 and a beta of 0.82. The company has a debt-to-equity ratio of 0.23, a current ratio of 1.27 and a quick ratio of 0.78.

Cooper Companies (NASDAQ:COO) last posted its quarterly earnings results on Wednesday, September 9th. The medical device company reported $1.15 earnings per share for the quarter, topping analysts’ consensus estimates of $1.12 by $0.03. The company had revenue of $1.07 billion for the quarter, compared to the consensus estimate of $1.10 billion. Cooper Companies had a net margin of 13.46% and a return on equity of 10.92%. Cooper Companies’s revenue was up .5% on a year-over-year basis. During the same quarter last year, the firm posted $0.49 earnings per share. Cooper Companies has set its Q4 2026 guidance at 1.050-1.090 EPS and its FY 2026 guidance at 4.510-4.550 EPS. As a group, equities analysts forecast that Cooper Companies will post 4.63 EPS for the current year.

Cooper Companies announced that its Board of Directors has authorized a stock buyback program on Wednesday, September 9th that authorizes the company to repurchase $3.00 billion in shares. This repurchase authorization authorizes the medical device company to buy up to 22.7% of its shares through open market purchases. Shares repurchase programs are usually a sign that the company’s board of directors believes its shares are undervalued.

Institutional Investors Weigh In On Cooper Companies

Several hedge funds have recently modified their holdings of COO. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its stake in shares of Cooper Companies by 48.9% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 22,407 shares of the medical device company’s stock valued at $1,890,000 after purchasing an additional 7,363 shares during the period. First Trust Advisors LP grew its holdings in Cooper Companies by 115.8% during the 2nd quarter. First Trust Advisors LP now owns 136,334 shares of the medical device company’s stock valued at $9,702,000 after purchasing an additional 73,165 shares in the last quarter. Cresset Asset Management LLC acquired a new stake in Cooper Companies during the 2nd quarter valued at $291,000. Cerity Partners LLC increased its stake in Cooper Companies by 4.4% during the 2nd quarter. Cerity Partners LLC now owns 17,870 shares of the medical device company’s stock worth $1,272,000 after buying an additional 757 shares during the period. Finally, Daiwa Securities Group Inc. increased its stake in Cooper Companies by 2.8% during the 2nd quarter. Daiwa Securities Group Inc. now owns 35,839 shares of the medical device company’s stock worth $2,551,000 after buying an additional 973 shares during the period. 24.39% of the stock is currently owned by hedge funds and other institutional investors.

Trending Headlines about Cooper Companies

Here are the key news stories impacting Cooper Companies this week:

• Positive Sentiment: Cooper reported fiscal Q3 adjusted EPS of $1.15, above the $1.12 consensus estimate. The company also generated $273 million in free cash flow and repurchased $339.1 million of stock. CooperCompanies Announces Third Quarter 2026 Results
• Positive Sentiment: The board increased its share-repurchase authorization from $2 billion to $3 billion, potentially allowing repurchases of up to 22.7% of outstanding shares and signaling that management views the stock as undervalued. CooperCompanies Completes Strategic Review
• Neutral Sentiment: Analysts remain divided: Needham maintained a “buy” rating despite lowering its target to $73, while JPMorgan, UBS and Bank of America cut targets and maintained neutral ratings. The revisions imply upside from recent levels but reflect reduced estimates and greater uncertainty.
• Negative Sentiment: Revenue totaled approximately $1.066 billion, below the $1.10 billion consensus, with CooperVision revenue flat year over year. Destocking and channel-inventory reductions in the U.S. pressured contact-lens demand and overshadowed the EPS beat. COO Q3 Earnings Top Estimates
• Negative Sentiment: Cooper cut fiscal 2026 adjusted EPS guidance to $4.51–$4.55 from expectations near $4.63, and forecast fourth-quarter EPS of $1.05–$1.09 versus consensus of $1.20. Investors also reacted negatively to the decision not to pursue a sale of CooperSurgical after the strategic review. Cooper Cos. Stock Drops After Soft Outlook
• Negative Sentiment: A securities-fraud investigation announced by the Law Offices of Frank R. Cruz adds headline and legal risk, although the announcement does not establish that Cooper violated securities laws. Securities Fraud Investigation Announcement

Cooper Companies Company Profile

Cooper Companies, Inc is a global medical device company headquartered in San Ramon, California. Founded in 1958, the company develops, manufactures and markets products through two primary business segments: CooperVision and CooperSurgical.

CooperVision specializes in contact lenses, including daily disposable, toric, multifocal, multifocal toric, specialty and myopia-management lenses. Its products are designed to address a range of vision-correction needs, including astigmatism, presbyopia and irregular corneas.